Recent antihypertensive studies have demonstrated that small peptides with angiotensin I-converting enzyme (ACE) inhibitory activity had an ability to lower or to modulate a pressor blood pressure response in mild hypertensive subjects. However, the underlying mechanisms still remain unclear. Based on our pre- 
Introduction
Angiotensin (Ang) II is a potent vasopressor hormone formed from Ang I by the action of Ang I-converting enzyme (ACE). The hemodynamic and proliferative effects of Ang II are caused by diverse intracellular signal responses in both endothelial cells (EC) and vascular smooth muscle cells (VSMCs) (1−3) . To retard the development of vascular lesions, the proliferation of VSMCs can be inhibited in any of three ways: 1) by suppressing the pressor Ang II production from Ang I, i.e., ACE inhibition; 2) by inhibiting Ang II binding to Ang II type 1 (AT1)-receptors, i.e., AT1-receptor-mediated signaling block; and 3) by suppressing Ca 2+ influx, i.e., voltage-gated Ltype Ca 2+ channel-blocking action. Numerous therapeutic drugs, including ACE inhibitors (4−6) and AT1-receptor antagonists (7, 8) , have been developed to accomplish the first two effects, while Ca 2+ channel blockers have been used to retard vascular lesions by the third mechanism (9) . Current studies on antihypertensive treatment have focused on the development of AT1-receptor antagonists (7, 8, 10) , since they modulate the renin-angiotensin system (RAS) more specifically than ACE inhibitors, and do not affect bradykinin and/or substance P levels, which are responsible for the well recognized side-effects of ACE inhibitors, such as dry cough and angioneurotic edema (11) . Ca 2+ channel blockers are also among the novel antihypertensive agents in that they have diverse therapeutic actions, including cardiodepressive and antiarrhythmic effects.
In the course of the development of antihypertensive drugs, several studies have examined natural ACE inhibitors with a view toward prophylaxis of hypertension disease through medicinal foods (12−14) . Clinical evidence of some antihypertensive foods has provided the efficacy of the food intake on blood pressure (BP) regulation (15−17) . In our previous, randomized double-blind placebo-controlled study in which a sardine peptide drink was given to volunteers with mild essential hypertension (15), Val-Tyr (VY) was shown to have ACE inhibitory activity and the ability to improve hypertension through the suppression of human RAS. More recently, other peptides with ACE inhibitory activity, such as Ile-(or Val)-Pro-Pro (16) or Leu-Lys-Pro-Asn-Met (17) , have also been revealed to have a mild antihypertensive effect in humans. On the other hand, although there have been many studies on the ACE inhibition of natural peptides, there has been no report on whether these peptides might also have effects on regional BP regulatory systems, such as the heart and vascular tissues, that were significant target organs of ACE inhibitory drugs (18) . Our recent study⎯in which the VY peptide did not inhibit the enhanced circulating human RAS in transgenic hypertensive mice bearing both the human renin gene and human angiotensinogen gene, although VY significantly lowered the BP of the hypertensive mice⎯has led us to an alternative strategy for elucidating peptideinduced antihypertensive actions (19) . The observation that the VY peptide is accumulated in organs such as the aorta and kidney at a concentration higher (0.26 μg/rat) than that in the blood (0.046 μg/rat) (20, 21) also supports the view that the peptide may play a role in regulating regional BP control systems. In addition, the report by Masuda et al. (22) revealed that Val-Pro-Pro was detected at a level of 4.3 μg/rat-aorta at 6 h after administration. However, the physiological role of these three peptides in vascular functions still remains unclear. In this report, therefore, we examined the ability of ACE inhibitory peptides, including VY, to inhibit the proliferation of VSMCs, and also revealed a novel antihypertensive mechanism of bioactive small peptides in cultured VSMCs. 
Methods

Materials
Cell Cultures
Human VSMCs were purchased from Sanko Junyaku Kogyo Co. (Tokyo, Japan) and cultured in smooth muscle cell growth medium-2 (SmBM) containing 5% fetal bovine serum (FBS), human epidermal growth factor (0.5 ng/ml), bovine insulin (5 μg/ml), human basic fibroblast growth factor-B (1 ng/ml), and GA-1000 (30 μg/ml of gentamicin sulfate and 15 ng/ml of amphotericin-B). The SmBM corresponds to 10 mmol/l HEPES buffer (pH 7.4) containing 145 mmol/l NaCl, 5 mmol/l KCl, 1 mmol/l Na2HPO4, 1 mmol/l CaCl2, 0.5 mmol/l MgSO4 and 5 mmol/l glucose. Cell preparations in 24-well tissue culture plates were kept at 37°C in a 5% CO2/ 95% O2 humidified atmosphere. For all experiments, VSMCs were grown to 70−90% confluence and made quiescent by serum-free SmBM for 24 h. Cells between passages 7 and 8 were used in this study.
Cell Counts and Cell Proliferation Assay
Cell numbers were determined by the Trypan blue dye exclusion method using a hemacytometer. VSMCs seeded in 24-well tissue culture plates (1.5 × 10 5 cells/well) were made quiescent by serum-free SmBM for 24 h to remove any serum cytokines or growth factors. After the 24 h-treatment, the medium was replaced by 5% FBS-SmBM in the presence or absence of peptides. The medium was exchanged for fresh medium every 48 h, and on day 5 of incubation the cells were removed by treatment with 0.1% trypsin/EDTA solution and the number of viable VSMCs was counted using a hemacytometer. Values are expressed as the means from two wells from triplicate experiments.
WST-8 Incorporation Assay
For cytotoxicity and mitogen-stimulated VSMC proliferation studies, a WST-8 incorporation experiment was performed, in which the rate of cell proliferation or DNA synthesis was determined by a nonradioactive colorimetric method on the basis of the cleavage of a tetrazolium salt rather than by a [ 3 H]thymidine incorporation assay (23) . VSMCs grown to subconfluence in 24-well tissue culture plates were made quiescent and inoculated onto 96-well tissue culture plates at a density of 1 × 10 4 cells/well. Cells incubated in serum-free SmBM for 24 h were treated for 48 h with mitogens in the presence or absence of antagonists and/or peptides. The mitogens were added a few minutes after the addition of antagonists and/or peptides. The medium was replaced with fresh medium 24 h after plating, and then an additional 24 h-incubation was performed. After the incubation, 0.5 μmol of WST-8 per well was added to the growth medium and incubated for 3 h. The WST-8 incorporation was determined by a Wallac 1420 Multilabel counter (Perkin Elmer Co., Tokyo, Japan) at 450 nm.
Analyses of Data
Each result is expressed as the mean ±SEM. Statistical differences between control and sample groups were evaluated by using a two-way analysis of variance (ANOVA) followed by the Tukey-Kramer's t-test for a post hoc analysis. Statistical differences between groups were analyzed by Student's t-test. Values of p< 0.05 were considered statistically significant. Analyses were performed with Stat View J 5.0 software (SAS Institute Inc., Cary, USA).
Results
Inhibition of VSMC Proliferation by ACE Inhibitory Peptides
We first investigated the effect of small peptides that are known to have in vitro ACE inhibitory activity at a concentration of 1 mmol/l on VSMC proliferation in 5% FBS-SmBM for 5 days. The peptides used in this series of experiments were IW, VY and IVY. IW (IC50 of 2.0 μmol/l) (24) and IVY (IC50 of 0.48 μmol/l) (14) were used because, among the dipeptides and tripeptides so far reported, they show two of the highest levels of ACE inhibitory activities. VY (IC50 of 26 μmol/l) was used (25) because it has been shown to have an antihypertensive effect in mild hypertensive subjects (15) , and to accumulate in aortic tissue after oral administration in rats (20) . As shown in Fig. 1 , among the three peptides, only VY caused a marked decrease in the serum-stimulated VSMC growth, to 54% of the number of serum-stimulated cells (control). This is the first finding that even a small natural peptide could inhibit VSMC proliferation. Although IVY also tended to cause a slight decrease in the growth, to 82% of the level in the control cells, IW, an ACE inhibitory peptide, did not elicit an antiproliferative effect, indicating that ACE inhibition is not responsible for the inhibition of the serum-stimulated proliferation. Cytotoxicity experiments of VY and IVY (Fig. 2) , in which a WST-8 incorporation assay was done for VSMCs treated in serum-free SmBM for 48 h in the presence or absence of 1 mmol/l of the peptides, revealed that the peptideinduced antiproliferative action was not due to any cytotoxic action. Figure 1 also shows that the VY-induced antiproliferation effect was elicited in a concentration-dependent manner. A significant VY-induced decrease of 21% (p< 0.05 vs. control), 41% (p< 0.01) and 46% (p< 0.01) in the cell number was observed at final VY concentrations of 0.05, 0.1 and 1 mmol/l, respectively; at least 50 μmol/l of VY was required to inhibit the serum-stimulated VSMC proliferation.
Antiproliferative Action Induced by Peptides in Ang II-Stimulated VSMCs
In order to clarify the antiproliferative mechanism of VY on the serum-stimulated VSMC growth, effects of VY on the signal-transduction pathway via AT1-receptor were examined. As shown in Fig. 3 , Ang II induced a significant mitogenic effect on the VSMCs treated for 48 h in serum-free SmBM; 1 μmol/l Ang II increased WST-8 incorporation by 179±9% (control) above the basal level (without Ang II). In the presence of the peptides at a concentration of 1 mmol/l, we observed a potent suppression of the WST-8 incorporation into the Ang II-stimulated VSMCs for VY with a reduction to 65% of the control. IVY also tended to suppress an increase in the incorporation by the Ang II stimulation (though a significant difference was not observed), whereas IW had no effect on the Ang II-induced WST-8 incorporation. Captopril as a typical ACE inhibitor (IC50 of 20 nmol/l ) (14) also showed no influence on the incorporation at a concentration of 1 μmol/l, strongly suggesting that the antiproliferative effect induced by VY was not a result of ACE inhibition. Inhibition of the Ang II-stimulated WST-8 incorporation by VY was elicited in a concentration-dependent manner over the range 1 μmol/l to 1 mmol/l, as shown in Fig. 4 . The concentration at which VY induced 50% inhibition of the WST-8 incorporation stimulated by 1 μmol/l Ang II (the IC50 value) was estimated to be 33±6 μmol/l.
Ang II-stimulated VSMCs in serum-free SmBM were treated with 1 mmol/l VY for 48 h in the presence or absence of 1 μmol/l of an AT1-receptor selective antagonist (losartan) and 1 μmol/l of a nonselective Ang II receptor antagonist (saralasin). As shown in Fig. 5 , VY inhibited the WST-8 incorporation into the Ang II-stimulated VSMCs, irrespective of the presence of losartan. The VY-induced inhibition of WST-8 incorporation was also independent of saralasin, indi- cating that some action of the peptide other than an antagonistic effect against Ang II receptors may be responsible for its antiproliferative effect on VSMCs.
Fig. 3. Effects of small peptides on angiotensin (Ang) IIinduced VSMC proliferation. VSMCs at a density of 1 × 10 4 cells/well were treated for 48 h with 1 μmol/l Ang II in the presence of 1 mmol/l peptides. Ang II was added a few minutes after the addition of peptides. After the incubation, the WST-8 incorporation was determined at 450 nm to evaluate the inhibition of mitogenic increase in the incorporation by peptides. The peptides used in this series of experiments were IW, VY, and IVY. Captopril (1 μmol/l) was also used as a typical ACE inhibitor. Each value is the mean ±SEM (n=6). Significant differences between the basal and control groups
Antiproliferative Action Induced by Peptides in Bay K 8644-Stimulated VSMCs
We next examined whether the small peptide VY achieved its inhibition of the proliferation of VSMCs by suppressing increases of the intracellular Ca 2+ concentration. Bay K 8644 was used as a mitogen or voltage-gated L-type Ca 2+ channel agonist to assess the inhibition of extracellular Ca 2+ influx by VY. Figure 6 shows the effect of VY on WST-8 incorporation for VSMCs in serum-free SmBM that contained 1 mmol/l CaCl2 in the presence or absence of 1 μmol/l Bay K 8644 for 48 h. The results showed that Bay K 8644 elicited a significant (p< 0.01) increase in the WST-8 incorporation; 1 μmol/l Bay K 8644 increased the WST-8 incorporation by 146 ±24% (control) above a basal level (without Bay K 8644). It was also revealed that 1 mmol/l VY significantly (p< 0.01) inhibited the increase in the WST-8 incorporation stimulated by 1 μmol/l Bay K 8644, as 1 μmol/l verapamil (a therapeutic Ltype Ca 2+ channel blocker) inhibited. In contrast, the presence of 1 μmol/l paxillin, which is a K + channel blocker, did not affect the inhibitory action of VY. This finding provided the first evidence that VY achieved its inhibition of VSMC proliferation by acting as a voltage-gated L-type Ca 2+ channel blocker, but not as a K + channel agonist. As shown in Fig. 7 , VY inhibited the incorporation in a concentration-dependent manner over the range of 10−1,000 μmol/l. The tentatively estimated IC50 value for inhibiting the incorporation by VY was 55 ±4 μmol/l (IC50 of verapamil: 30±2 nmol/l).
Discussion
In the present study, we provided the first evidence that a small peptide with ACE inhibitory activity had the additional antihypertensive effects of inhibiting the proliferation of VSMCs, inhibiting mitogen-stimulated DNA synthesis in a concentration-dependent manner, and reducing serum-stimulated cell growth without cytotoxicity. Vascular functional and structural alternations are critical for hypertension disease including vascular or arteriosclerotic lesions (26) . VSMC proliferation, hypertrophy or migration is induced by Ang II and/or norepinephrine stimulation, and Ang II has also been shown to act as an autocrine/paracrine mediator in the RAS and to play a prominent role in the pathogenesis of vascular lesions via upregulation of the proliferation of VSMCs (27) . Thus, an appropriate inhibition of Ang II production or Ang II-stimulated signaling pathways would be beneficial for diseases involving vascular lesions. Studies have shown that Ang II-induced VSMC proliferation could be successfully prevented by an AT1-receptor antagonist (7), a Ca 2+ channel blocker (28) , troglitazone (29) , Ang(1−7) (30), quercetin (31), docosahexaenoic acid (DHA)/eicosapentaenoic acid (EPA) (32) , genistein (33) and β-sitosterol (34). The antiproliferative mechanism of the latter natural compounds was considered to be due, at least in part, to the inhibition of such intracellular signal-transduction pathways as matrix metalloprotease-9 (MMP-9) secretion (31), phosphorylation of cyclin/cyclin dependent kinases (CDKs) (32) , and expressions of NAD(P)H oxidase and AT1 receptor (33) , but the precise mechanism remains poorly understood. Additionally, there has been no report that small peptides had the potential to inhibit VSMC proliferation in the manner of the Ang(1−7) peptide (30) .
Our present findings show that, among the ACE inhibitory di-and tri-peptides tested, only VY induced a potent VSMC growth inhibition in 5% FBS-SmBM for 5 days (Fig. 1) . The lack of an association between the antiproliferative effect and ACE inhibitory activity, and the fact that VY had no cytotoxic effect on VSMCs (Fig. 2) , indicated that some action of the peptide other than ACE inhibition may have been responsible for its antiproliferative effect on VSMCs. Freeman et al. (30) have reported the antiproliferative effect of a hepta-peptide, Ang(1−7), in VSMCs, which is mediated by an Ang(1−7)-sensitive receptor distinct from AT1 or AT2 receptors (30, 35) . However, it seems unlikely that VSMCs possess a small peptide (VY)-specific receptor that can influence the growth, because the smaller peptide would not act as a ligand for the G protein-coupled receptor.
Ang II stimulation was shown to promote DNA synthesis in VSMCs in serum-free medium, and the maximal increase in [ 3 H]thymidine incorporation was observed at an Ang II concentration of 1.75 μmol/l (36). The effect in response to Ang II was coupled to AT1 receptor-mediated signaling transduction pathways. In the present study, the increase in WST-8 incorporation by 1 μmol/l Ang II was prevented by 1 mmol/l VY, whereas captopril as an ACE inhibitor did not affect the incorporation (Fig. 3) . The finding that an ACE inhibitor had no effect on the Ang II-stimulated VSMC incorporation was in agreement with the result by Watanabe et al. (36) , suggesting that the role of ACE inhibitors was restricted to the suppression of Ang II production, and did not include inhibition of Ang II-signaling pathways in VSMCs. Although the VYinduced antiproliferative effect (IC50 of 33±6 μmol/l) was much weaker than those of des-[Asp 1 ]-Ang I (37) and Ang(1− 7) (30), the present study reveals that the "ACE inhibitory" peptide played a physiological role in regulating the VSMC growth. The antiproliferative action of VY on the Ang IIstimulated VSMCs was observed even in the presence of an Ang II receptor antagonist (saralasin or losartan) (Fig. 5) . This indicates that the VY-induced antiproliferative action may not be responsible for the antagonistic effect against Ang II receptors.
Hence, we focused on another VSMC proliferative pathway. Apparently, VY inhibited the WST-8 incorporation in the L-type Ca 2+ channel agonist (Bay K 8644)-stimulated VSMCs in a concentration-dependent manner over the range of 0.01−1 mmol/l (Fig. 7) , just as verapamil (a voltage-gated L-type Ca 2+ channel blocker) did. The effect induced by VY was not abolished by paxillin as a K + channel blocker (Fig. 6 ). Thus, it seems likely that VY may inhibit extracellular Ca 2+ influx via L-type Ca 2+ channels in the manner of verapamil (38) . On the other hand, Umemoto et al. (39) reported that another Ca 2+ antagonist, amlodipine, inhibited the vascular oxidative stress induced by activated NAD(P)H oxidase, which implies that other mechanisms such as oxidative stress, inositol phosphate-3 binding (3), or myosin light chain kinase activation by facilitation of Ca 2+ /calmodulin signaling, may likewise contribute to the VY-induced antiproliferative action. Further experiments are currently in progress to elucidate the mechanism of antiproliferation induced by small peptides in VSMCs.
In conclusion, we demonstrated that a small peptide, VY, exerted an antiproliferative effect on VSMCs. The effect of VY did not involve ACE inhibition, but may have been due to an inhibition of L-type Ca 2+ influx. These findings suggest the possibility of developing novel medicinal foods to prevent diseases involving vascular lesions, such as arteriosclerosis, insulin-resistance and vascular restenosis. 
